Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Revenue (2016 - 2025)

Historic Revenue for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $5000.0.

  • Altimmune's Revenue changed 0.0% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $20000.0, marking a year-over-year decrease of 6153.85%. This contributed to the annual value of $20000.0 for FY2024, which is 9530.52% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Revenue is $5000.0, which was down 0.0% from $5000.0 recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Revenue peaked at $3.3 million during Q4 2021, and registered a low of $2000.0 during Q3 2022.
  • Its 5-year average for Revenue is $259947.4, with a median of $8000.0 in 2022.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 9920.66% in 2022, then skyrocketed by 1800000.0% in 2023.
  • Quarter analysis of 5 years shows Altimmune's Revenue stood at $3.3 million in 2021, then plummeted by 99.21% to $26000.0 in 2022, then skyrocketed by 42.31% to $37000.0 in 2023, then crashed by 86.49% to $5000.0 in 2024, then changed by 0.0% to $5000.0 in 2025.
  • Its last three reported values are $5000.0 in Q3 2025, $5000.0 for Q2 2025, and $5000.0 during Q1 2025.